Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Leases (2021 - 2025)

Historic Current Leases for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $408122.0.

  • InMed Pharmaceuticals' Current Leases fell 276.12% to $408122.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $408122.0, marking a year-over-year decrease of 276.12%. This contributed to the annual value of $435507.0 for FY2025, which is 3703.94% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Current Leases of $408122.0 as of Q4 2025, which was down 276.12% from $424765.0 recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Current Leases high stood at $435507.0 for Q2 2025, and its period low was $82232.0 during Q3 2021.
  • Over the past 5 years, InMed Pharmaceuticals' median Current Leases value was $404219.5 (recorded in 2022), while the average stood at $375450.9.
  • Per our database at Business Quant, InMed Pharmaceuticals' Current Leases surged by 39149.11% in 2022 and then tumbled by 2750.5% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Current Leases (Quarter) stood at $391805.0 in 2021, then increased by 5.74% to $414307.0 in 2022, then dropped by 12.1% to $364190.0 in 2023, then increased by 15.25% to $419711.0 in 2024, then dropped by 2.76% to $408122.0 in 2025.
  • Its Current Leases was $408122.0 in Q4 2025, compared to $424765.0 in Q3 2025 and $435507.0 in Q2 2025.